dc.contributor
Institut Català de la Salut
dc.contributor
[Pretelli G] Department of Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Mati K] Oncology Unit, SALUS Hospital, Tirana, Albania. [Motta L] Medical Oncology Unit, Humanitas Istituto Clinico Catanese, Catania, Italy. Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy. [Stathis A] Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland. Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Pretelli, Giulia
dc.contributor.author
Mati, Kleida
dc.contributor.author
Motta, Lucia
dc.contributor.author
STATHIS, ANASTASIOS
dc.date.accessioned
2025-10-25T05:37:34Z
dc.date.available
2025-10-25T05:37:34Z
dc.date.issued
2024-07-12T09:11:27Z
dc.date.issued
2024-07-12T09:11:27Z
dc.date.issued
2024-06-27
dc.identifier
Pretelli G, Mati K, Motta L, Stathis A. Antibody-drug conjugates combinations in cancer treatment. Explor Target Anti-tumor Ther. 2024 Jun 27;5(3):714–41.
dc.identifier
https://hdl.handle.net/11351/11703
dc.identifier
10.37349/etat.2024.00243
dc.identifier.uri
http://hdl.handle.net/11351/11703
dc.description.abstract
Antibody-drug conjugates; Combination regimens; Novel anticancer therapies
dc.description.abstract
Conjugados anticuerpo-fármaco; Regímenes combinados; Nuevas terapias anticancerígenas
dc.description.abstract
Conjugats anticòs-fàrmac; Règims combinats; Noves teràpies anticancerígenes
dc.description.abstract
Antibody-drug conjugates (ADCs) have emerged as a promising class of anticancer agents. Currently, the Food and Drug Administration has granted approval to 12 compounds, with 2 later undergoing withdrawal. Moreover, several other compounds are currently under clinical development at different stages. Despite substantial antitumoral activity observed among different tumor types, adverse events and the development of resistance represent significant challenges in their use. Over the last years, an increasing number of clinical trials have been testing these drugs in different combinations with other anticancer agents, such as traditional chemotherapy, immune checkpoint inhibitors, monoclonal antibodies, and small targeted agents, reporting promising results based on possible synergistic effects and a potential for improved treatment outcomes among different tumor types. Here we will review combinations of ADCs with other antitumor agents aiming at describing the current state of the art and future directions.
dc.format
application/pdf
dc.publisher
Open Exploration
dc.relation
Exploration of Targeted Anti-tumor Therapy;5(3)
dc.relation
https://doi.org/10.37349/etat.2024.00243
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Càncer - Tractament
dc.subject
Immunoglobulines - Ús terapèutic
dc.subject
Medicaments antineoplàstics - Ús terapèutic
dc.subject
Resistència als medicaments
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Immunoconjugates
dc.subject
PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm
dc.subject
DISEASES::Neoplasms
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Immunological
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::globulinas séricas::inmunoglobulinas::anticuerpos::inmunoconjugados
dc.subject
FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicos
dc.subject
ENFERMEDADES::neoplasias
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásica
dc.title
Antibody-drug conjugates combinations in cancer treatment
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
